Genetic Deletion of p90 Ribosomal S6 Kinase 2 Alters Patterns of 5-Hydroxytryptamine2A Serotonin Receptor Functional Selectivity
The concept of functional selectivity has now thoroughly supplanted the previously entrenched notion of intrinsic efficacy by explaining how agonists and antagonists exhibit a range of efficacies for distinct receptor-mediated responses. It is noteworthy that functional selectivity accommodates sign...
Saved in:
Published in | Molecular pharmacology Vol. 77; no. 3; pp. 327 - 338 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
The American Society for Pharmacology and Experimental Therapeutics
01.03.2010
|
Online Access | Get full text |
Cover
Loading…
Abstract | The concept of functional selectivity has now thoroughly supplanted the previously entrenched notion of intrinsic efficacy by explaining how agonists and antagonists exhibit a range of efficacies for distinct receptor-mediated responses. It is noteworthy that functional selectivity accommodates significant changes in efficacy resulting from differential expression of G protein-coupled receptor modifying proteins (i.e., “conditional efficacy”)—a phenomenon with profound implications for drug discovery. We have uncovered a novel regulatory mechanism whereby p90 ribosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine
2A
(5-HT
2A
) serotonin receptors and attenuates receptor signaling via direct receptor phosphorylation (
Proc Natl Acad Sci U S A
103:
4717–4722, 2006;
J Biol Chem
284:
5557–5573, 2009). This discovery, together with the mounting evidence for conditional efficacy, suggested to us that 5-HT
2A
agonist signaling might be disproportionately affected by alterations in RSK2 expression. To test this hypothesis, we evaluated a chemically diverse set of 5-HT
2A
agonists at three readouts of 5-HT
2A
receptor activation in both wild-type (WT) and RSK2 knock-out (KO) mouse embryonic fibroblasts (MEFs). Here we report that 5-HT
2A
receptor agonist efficacies were significantly and variably augmented in RSK2 KO MEFs compared with WT MEFs. As a result, relative agonist efficacies were significantly altered, and even reversed, between WT and RSK2 KO MEFs for a single effector readout. This study provides the first evidence that deletion of a single kinase can elicit profound changes in patterns of agonist functional selectivity. |
---|---|
AbstractList | The concept of functional selectivity has now thoroughly supplanted the previously entrenched notion of intrinsic efficacy by explaining how agonists and antagonists exhibit a range of efficacies for distinct receptor-mediated responses. It is noteworthy that functional selectivity accommodates significant changes in efficacy resulting from differential expression of G protein-coupled receptor modifying proteins (i.e., “conditional efficacy”)—a phenomenon with profound implications for drug discovery. We have uncovered a novel regulatory mechanism whereby p90 ribosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine
2A
(5-HT
2A
) serotonin receptors and attenuates receptor signaling via direct receptor phosphorylation (
Proc Natl Acad Sci U S A
103:
4717–4722, 2006;
J Biol Chem
284:
5557–5573, 2009). This discovery, together with the mounting evidence for conditional efficacy, suggested to us that 5-HT
2A
agonist signaling might be disproportionately affected by alterations in RSK2 expression. To test this hypothesis, we evaluated a chemically diverse set of 5-HT
2A
agonists at three readouts of 5-HT
2A
receptor activation in both wild-type (WT) and RSK2 knock-out (KO) mouse embryonic fibroblasts (MEFs). Here we report that 5-HT
2A
receptor agonist efficacies were significantly and variably augmented in RSK2 KO MEFs compared with WT MEFs. As a result, relative agonist efficacies were significantly altered, and even reversed, between WT and RSK2 KO MEFs for a single effector readout. This study provides the first evidence that deletion of a single kinase can elicit profound changes in patterns of agonist functional selectivity. |
Author | Strachan, Ryan T. Cronan, Mark R. Kroeze, Wesley K. Sciaky, Noah Roth, Bryan L. |
Author_xml | – sequence: 1 givenname: Ryan T. surname: Strachan fullname: Strachan, Ryan T. – sequence: 2 givenname: Noah surname: Sciaky fullname: Sciaky, Noah – sequence: 3 givenname: Mark R. surname: Cronan fullname: Cronan, Mark R. – sequence: 4 givenname: Wesley K. surname: Kroeze fullname: Kroeze, Wesley K. – sequence: 5 givenname: Bryan L. surname: Roth fullname: Roth, Bryan L. |
BookMark | eNpVj09Lw0AUxBep2D969bxfIPW9zW6aXIRSbSsWlFbBW9gmL7qS7IZkW8zNj26KXjz9BmaYYcZsYJ0lxq4RpohC3lSunCIkU4hQSjhjI1QCA0DEARsBiCiIE_U2ZOO2_QRAqWK4YENMkjCUgCP2vSJL3mT8jsqeznJX8DoBvjV717pKl3wX8UdjdUtc8HnpqWn5s_Y9bXsKq2Dd5Y376nzT1V5XxpKY8x01zjtrLN9SRrV3DV8ebHZaOFX2Y70-Gt9dsvNCly1d_XHCXpf3L4t1sHlaPSzmm6DGSEEQaUpmQuVCaiwERqhJxZmKZV6AzpNwluv-dKhiyvJwLwuIZsUs1qQpB1lIDCfs9re3PuwryjOyvtFlWjem0k2XOm3S_441H-m7O6YiDpUUEP4AVxlxNA |
ContentType | Journal Article |
Copyright | Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics |
Copyright_xml | – notice: Copyright © 2010 The American Society for Pharmacology and Experimental Therapeutics |
DBID | 5PM |
DOI | 10.1124/mol.109.061440 |
DatabaseName | PubMed Central (Full Participant titles) |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0111 |
EndPage | 338 |
GrantInformation_xml | – fundername: National Institutes of Health grantid: R01-MH61887; U19-MH82441 |
GroupedDBID | --- -~X .55 0R~ 123 18M 2WC 34G 39C 4.4 53G 5PM 5RE 5VS ABCQX ABJNI ABSQV ACGFO ACGFS ADCOW AENEX AFFNX AFHIN AFOSN ALMA_UNASSIGNED_HOLDINGS CS3 DIK E3Z EBS EJD F5P F9R GX1 H13 HH5 HZ~ IH2 INIJC KQ8 L7B N9A O9- OK1 P2P R.V R0Z RHF RHI RPT TR2 W8F WOQ X7M YBU YHG |
ID | FETCH-LOGICAL-p1650-6ae9725d24a1f2161ae58c584df0ad937da011358ecd3b4f067f78aeaed04f413 |
ISSN | 0026-895X |
IngestDate | Tue Sep 17 21:27:36 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p1650-6ae9725d24a1f2161ae58c584df0ad937da011358ecd3b4f067f78aeaed04f413 |
OpenAccessLink | https://europepmc.org/articles/pmc2835420?pdf=render |
PMID | 19933401 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2835420 |
PublicationCentury | 2000 |
PublicationDate | 20100301 |
PublicationDateYYYYMMDD | 2010-03-01 |
PublicationDate_xml | – month: 3 year: 2010 text: 20100301 day: 1 |
PublicationDecade | 2010 |
PublicationTitle | Molecular pharmacology |
PublicationYear | 2010 |
Publisher | The American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: The American Society for Pharmacology and Experimental Therapeutics |
SSID | ssj0014580 |
Score | 2.164169 |
Snippet | The concept of functional selectivity has now thoroughly supplanted the previously entrenched notion of intrinsic efficacy by explaining how agonists and... |
SourceID | pubmedcentral |
SourceType | Open Access Repository |
StartPage | 327 |
Title | Genetic Deletion of p90 Ribosomal S6 Kinase 2 Alters Patterns of 5-Hydroxytryptamine2A Serotonin Receptor Functional Selectivity |
URI | https://pubmed.ncbi.nlm.nih.gov/PMC2835420 |
Volume | 77 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV09b9swECXcdOlS9BP9BociiyJXpihZGg03qVHDQZA4qLeAEilUQC0JjjI4U391596RtES3Gdp4EAxZlizdM3n3ePeOkI-SKyGCLPZVlhc-HxWhn2UQrORKRlLAK-RYnLw4jWeX_OsqWg0Gv5yspZs2G-a3d9aV3MeqsA_silWy_2HZ7qSwA96DfWELFobtP9kYNaNRcPWzQglt4_k1aeCdl1l9Xa9R6CP25mUFM5XHvAkujF-jKD-SgDqFI_JnW4mJLO1m27RiDS4nm-D4UbdI06JTqRqIyr0TmP4sa3ihO-fonhOuZ7vY9dn1ml4Nu-PrUQQXa4y1RbcwpiyH_RJQKQyBe1r35PR0U9vOyVhN5J13h883tbrVLOw3hYS7Nx-6zAUuuocuc7HsS2eqvRzVM-dn6iWUY7fZwbKvS3PpTIgl_SSNVmZes4M5Q6rEDuZ2tLdNY0qXDNBDd2g0CqwXEBrNmb8nGMYBFev6B-pwDXU4HbgHAkCatYYbZkaG3N7vns732WKKKnecBQ_IQxRwxJ4PX1ZdatKIR4kpnbL3ZMVG4dqf9q-sJW_NZf5M6nW8pOUT8tiGN3RisPqUDFT1jBzaR709ou5jPaKH1DXCc_LTApruAE3rggKgaQdoehFTA2jKqAE03QEaD74T0LQDNN0BmvaApg6gX5DLk-PldObbFiF-M4LYwo-FSscskoyLUcEgehEqSnJwqmURCAmutxQAgDBKVC7DjBfgmxXjRCihZMALcOBekoOqrtQrQlmRF0kapzJHhi9LM6XGKhAQ7qQyYEK8JuO9B3zVGDmYKxRo3_-kKr9roXZr5Tf3_uZb8qj_47wjB-3mRr0HJ7jNPmjE_Aai1b4R |
link.rule.ids | 230,314,780,784,885,27924,27925 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+Deletion+of+p90+Ribosomal+S6+Kinase+2+Alters+Patterns+of+5-Hydroxytryptamine2A+Serotonin+Receptor+Functional+Selectivity&rft.jtitle=Molecular+pharmacology&rft.au=Strachan%2C+Ryan+T.&rft.au=Sciaky%2C+Noah&rft.au=Cronan%2C+Mark+R.&rft.au=Kroeze%2C+Wesley+K.&rft.date=2010-03-01&rft.pub=The+American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0026-895X&rft.eissn=1521-0111&rft.volume=77&rft.issue=3&rft.spage=327&rft.epage=338&rft_id=info:doi/10.1124%2Fmol.109.061440&rft_id=info%3Apmid%2F19933401&rft.externalDBID=PMC2835420 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon |